

COVID-19 Impact on Medicine for Osteoarthritis Pain Market, Global Research Reports 2020-2021

<https://marketpublishers.com/r/C1C3746CF69EEN.html>

Date: June 2020

Pages: 108

Price: US\$ 3,250.00 (Single User License)

ID: C1C3746CF69EEN

Abstracts

This report covers market size and forecasts of Medicine for Osteoarthritis Pain, including the following market information:

Global Medicine for Osteoarthritis Pain Market Size, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Medicine for Osteoarthritis Pain Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Medicine for Osteoarthritis Pain Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Medicine for Osteoarthritis Pain Market Size by Company, 2019- 2020 (quarterly data), (US\$ Million) & (K Units)

Key market players

Major competitors identified in this market include Pfizer, Johnson and Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma, etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)

North America (US and Canada)

Europe (Germany, France, UK and Italy)

Rest of World (Latin America, Middle East & Africa)

Based on the Type:

Oral

Injection

External

Based on the Application:

Medical Care

Personal Care

Contents

- 1.1 Research Scope
- 1.2 Market Segmentation
- 1.3 Research Objectives
- 1.4 Research Methodology
 - 1.4.1 Research Process
 - 1.4.2 Data Triangulation
 - 1.4.3 Research Approach
 - 1.4.4 Base Year
- 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
 - 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.5.2 Covid-19 Impact: Commodity Prices Indices
 - 1.5.3 Covid-19 Impact: Global Major Government Policy
- 1.6 The Covid-19 Impact on Medicine for Osteoarthritis Pain Industry
- 1.7 COVID-19 Impact: Medicine for Osteoarthritis Pain Market Trends

2 GLOBAL MEDICINE FOR OSTEOARTHRITIS PAIN QUARTERLY MARKET SIZE ANALYSIS

- 2.1 Medicine for Osteoarthritis Pain Business Impact Assessment - COVID-19
 - 2.1.1 Global Medicine for Osteoarthritis Pain Market Size, Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026
 - 2.1.2 Global Medicine for Osteoarthritis Pain Price, Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026
- 2.2 Global Medicine for Osteoarthritis Pain Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
 - 2.3.1 Drivers
 - 2.3.2 Restraints
 - 2.3.3 Opportunities
 - 2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

- 3.1 Global Medicine for Osteoarthritis Pain Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Medicine for Osteoarthritis Pain Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Medicine for Osteoarthritis Pain Manufacturing

Factories and Area Served

3.4 Date of Key Manufacturers Enter into Medicine for Osteoarthritis Pain Market

3.5 Key Manufacturers Medicine for Osteoarthritis Pain Product Offered

3.6 Mergers & Acquisitions, Expansion Plans

4 IMPACT OF COVID-19 ON MEDICINE FOR OSTEOARTHRITIS PAIN SEGMENTS, BY TYPE

4.1 Introduction

1.4.1 Oral

1.4.2 Injection

1.4.3 External

4.2 By Type, Global Medicine for Osteoarthritis Pain Market Size, 2019-2021

4.2.1 By Type, Global Medicine for Osteoarthritis Pain Market Size by Type, 2020-2021

4.2.2 By Type, Global Medicine for Osteoarthritis Pain Price, 2020-2021

5 IMPACT OF COVID-19 ON MEDICINE FOR OSTEOARTHRITIS PAIN SEGMENTS, BY APPLICATION

5.1 Overview

5.5.1 Medical Care

5.5.2 Personal Care

5.2 By Application, Global Medicine for Osteoarthritis Pain Market Size, 2019-2021

5.2.1 By Application, Global Medicine for Osteoarthritis Pain Market Size by Application, 2019-2021

5.2.2 By Application, Global Medicine for Osteoarthritis Pain Price, 2020-2021

6 GEOGRAPHIC ANALYSIS

6.1 Introduction

6.2 North America

6.2.1 Macroeconomic Indicators of US

6.2.2 US

6.2.3 Canada

6.3 Europe

6.3.1 Macroeconomic Indicators of Europe

6.3.2 Germany

6.3.3 France

6.3.4 UK

6.3.5 Italy

6.4 Asia-Pacific

6.4.1 Macroeconomic Indicators of Asia-Pacific

6.4.2 China

6.4.3 Japan

6.4.4 South Korea

6.4.5 India

6.4.6 ASEAN

6.5 Rest of World

6.5.1 Latin America

6.5.2 Middle East and Africa

7 COMPANY PROFILES

7.1 Pfizer

7.1.1 Pfizer Business Overview

7.1.2 Pfizer Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020

7.1.3 Pfizer Medicine for Osteoarthritis Pain Product Introduction

7.1.4 Pfizer Response to COVID-19 and Related Developments

7.2 Johnson and Johnson

7.2.1 Johnson and Johnson Business Overview

7.2.2 Johnson and Johnson Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020

7.2.3 Johnson and Johnson Medicine for Osteoarthritis Pain Product Introduction

7.2.4 Johnson and Johnson Response to COVID-19 and Related Developments

7.3 GlaxoSmithKline

7.3.1 GlaxoSmithKline Business Overview

7.3.2 GlaxoSmithKline Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020

7.3.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Product Introduction

7.3.4 GlaxoSmithKline Response to COVID-19 and Related Developments

7.4 Bayer

7.4.1 Bayer Business Overview

7.4.2 Bayer Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020

7.4.3 Bayer Medicine for Osteoarthritis Pain Product Introduction

7.4.4 Bayer Response to COVID-19 and Related Developments

7.5 Eli Lilly

7.5.1 Eli Lilly Business Overview

- 7.5.2 Eli Lilly Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
- 7.5.3 Eli Lilly Medicine for Osteoarthritis Pain Product Introduction
- 7.5.4 Eli Lilly Response to COVID-19 and Related Developments
- 7.6 Novartis
 - 7.6.1 Novartis Business Overview
 - 7.6.2 Novartis Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.6.3 Novartis Medicine for Osteoarthritis Pain Product Introduction
 - 7.6.4 Novartis Response to COVID-19 and Related Developments
- 7.7 Sanofi
 - 7.7.1 Sanofi Business Overview
 - 7.7.2 Sanofi Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.7.3 Sanofi Medicine for Osteoarthritis Pain Product Introduction
 - 7.7.4 Sanofi Response to COVID-19 and Related Developments
- 7.8 Horizon Pharma
 - 7.8.1 Horizon Pharma Business Overview
 - 7.8.2 Horizon Pharma Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.8.3 Horizon Pharma Medicine for Osteoarthritis Pain Product Introduction
 - 7.8.4 Horizon Pharma Response to COVID-19 and Related Developments
- 7.9 Abbott
 - 7.9.1 Abbott Business Overview
 - 7.9.2 Abbott Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.9.3 Abbott Medicine for Osteoarthritis Pain Product Introduction
 - 7.9.4 Abbott Response to COVID-19 and Related Developments
- 7.10 Mylan
 - 7.10.1 Mylan Business Overview
 - 7.10.2 Mylan Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.10.3 Mylan Medicine for Osteoarthritis Pain Product Introduction
 - 7.10.4 Mylan Response to COVID-19 and Related Developments
- 7.11 Daiichi Sankyo
 - 7.11.1 Daiichi Sankyo Business Overview
 - 7.11.2 Daiichi Sankyo Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Product Introduction
 - 7.11.4 Daiichi Sankyo Response to COVID-19 and Related Developments
- 7.12 TEVA
 - 7.12.1 TEVA Business Overview
 - 7.12.2 TEVA Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020

- 7.12.3 TEVA Medicine for Osteoarthritis Pain Product Introduction
- 7.12.4 TEVA Response to COVID-19 and Related Developments
- 7.13 Almatica Pharma
 - 7.13.1 Almatica Pharma Business Overview
 - 7.13.2 Almatica Pharma Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.13.3 Almatica Pharma Medicine for Osteoarthritis Pain Product Introduction
 - 7.13.4 Almatica Pharma Response to COVID-19 and Related Developments
- 7.14 Astellas Pharma
 - 7.14.1 Astellas Pharma Business Overview
 - 7.14.2 Astellas Pharma Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.14.3 Astellas Pharma Medicine for Osteoarthritis Pain Product Introduction
 - 7.14.4 Astellas Pharma Response to COVID-19 and Related Developments
- 7.15 Tide Pharmaceutical
 - 7.15.1 Tide Pharmaceutical Business Overview
 - 7.15.2 Tide Pharmaceutical Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.15.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Introduction
 - 7.15.4 Tide Pharmaceutical Response to COVID-19 and Related Developments
- 7.16 Iroko Pharmaceuticals
 - 7.16.1 Iroko Pharmaceuticals Business Overview
 - 7.16.2 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.16.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Introduction
 - 7.16.4 Iroko Pharmaceuticals Response to COVID-19 and Related Developments
- 7.17 Hengrui Pharmaceutical
 - 7.17.1 Hengrui Pharmaceutical Business Overview
 - 7.17.2 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.17.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Introduction
 - 7.17.4 Hengrui Pharmaceutical Response to COVID-19 and Related Developments
- 7.18 Abiogen Pharma
 - 7.18.1 Abiogen Pharma Business Overview
 - 7.18.2 Abiogen Pharma Medicine for Osteoarthritis Pain Quarterly Production and Revenue, 2020
 - 7.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Product Introduction
 - 7.18.4 Abiogen Pharma Response to COVID-19 and Related Developments

8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS

8.1 Medicine for Osteoarthritis Pain Supply Chain Analysis

8.1.1 Medicine for Osteoarthritis Pain Supply Chain Analysis

8.1.2 Covid-19 Impact on Medicine for Osteoarthritis Pain Supply Chain

8.2 Distribution Channels Analysis

8.2.1 Medicine for Osteoarthritis Pain Distribution Channels

8.2.2 Covid-19 Impact on Medicine for Osteoarthritis Pain Distribution Channels

8.2.3 Medicine for Osteoarthritis Pain Distributors

8.3 Medicine for Osteoarthritis Pain Customers

9 KEY FINDINGS

10 APPENDIX

10.1 About Us

10.2 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on Medicine for Osteoarthritis Pain Assessment

Table 9. COVID-19 Impact: Medicine for Osteoarthritis Pain Market Trends

Table 10. COVID-19 Impact Global Medicine for Osteoarthritis Pain Market Size

Table 11. Global Medicine for Osteoarthritis Pain Market Size Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026 (K Units)

Table 12. Global Medicine for Osteoarthritis Pain Price, Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026, (USD/Unit)

Table 13. Global Medicine for Osteoarthritis Pain Quarterly Market Size, 2020 (US\$ Million) & (K Units)

Table 14. Global Medicine for Osteoarthritis Pain Market Size, Pre-COVID-19 and Post-COVID-19 Quarterly Comparison, 2020-2021 (US\$ Million)

Table 15. Global Medicine for Osteoarthritis Pain Market Size, Pre-COVID-19 and Post-COVID-19 Quarterly Comparison, 2020-2021 (K Units)

Table 16. Global Medicine for Osteoarthritis Pain Market Growth Drivers

Table 17. Global Medicine for Osteoarthritis Pain Market Restraints

Table 18. Global Medicine for Osteoarthritis Pain Market Opportunities

Table 19. Global Medicine for Osteoarthritis Pain Market Challenges

Table 20. Key Manufacturers Medicine for Osteoarthritis Pain Quarterly Revenue, 2019 VS 2020 (US\$ Million)

Table 21. Top Manufacturers, Medicine for Osteoarthritis Pain Market Size, 2019 (K Units) & (US\$ Million)

Table 22. Medicine for Osteoarthritis Pain Factory Price by Manufacturers 2020

(USD/Unit)

Table 23. Location of Key Manufacturers Medicine for Osteoarthritis Pain Manufacturing Plants

Table 24. Key Manufacturers Medicine for Osteoarthritis Pain Market Served

Table 25. Date of Key Manufacturers Enter into Medicine for Osteoarthritis Pain Market

Table 26. Key Manufacturers Medicine for Osteoarthritis Pain Product Type

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Medicine for Osteoarthritis Pain Market Size by Type, 2020, (US\$ Million)

Table 29. Global Medicine for Osteoarthritis Pain Market Size by Type, 2020 (K Units)

Table 30. Global Medicine for Osteoarthritis Pain Price: by Type, 2020-2021 (USD/Unit)

Table 31. Global Medicine for Osteoarthritis Pain Market Size by Application: 2020-2021 (US\$ Million)

Table 32. Global Medicine for Osteoarthritis Pain Market Size by Application, 2020-2021 (K Units)

Table 33. Global Medicine for Osteoarthritis Pain Price: by Application, 2020-2021 (USD/Unit)

Table 34. Global Medicine for Osteoarthritis Pain Market Size by Region, 2019-2021 (US\$ Million)

Table 35. Global Medicine for Osteoarthritis Pain Market Size by Region, 2019-2021 (K Units)

Table 36. By Country, North America Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million)

Table 37. By Country, North America Medicine for Osteoarthritis Pain Market Size, 2019-2021 (K Units)

Table 38. US Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 39. Canada Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 41. By Country, Europe Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million)

Table 42. By Country, Europe Medicine for Osteoarthritis Pain Market Size, 2019-2021 (K Units)

Table 43. Germany Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 44. France Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 45. UK Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) &

(K Units)

Table 46. Italy Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 48. By Region, Asia-Pacific Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million)

Table 49. By Region, Asia-Pacific Medicine for Osteoarthritis Pain Market Size, 2019-2021 (K Units)

Table 50. China Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 51. Japan Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 52. South Korea Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 53. India Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 54. ASEAN Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 55. Latin America Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 56. Middle East and Africa Medicine for Osteoarthritis Pain Market Size, 2019-2021 (US\$ Million) & (K Units)

Table 57. Pfizer Business Overview

Table 58. Pfizer Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 59. Pfizer Medicine for Osteoarthritis Pain Product

Table 60. Pfizer Response to COVID-19 and Related Developments

Table 61. Johnson and Johnson Business Overview

Table 62. Johnson and Johnson Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 63. Johnson and Johnson Medicine for Osteoarthritis Pain Product

Table 64. Johnson and Johnson Response to COVID-19 and Related Developments

Table 65. GlaxoSmithKline Business Overview

Table 66. GlaxoSmithKline Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 67. GlaxoSmithKline Medicine for Osteoarthritis Pain Product

Table 68. GlaxoSmithKline Response to COVID-19 and Related Developments

Table 69. Bayer Business Overview

Table 70. Bayer Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 71. Bayer Medicine for Osteoarthritis Pain Product

Table 72. Bayer Response to COVID-19 and Related Developments

Table 73. Eli Lilly Business Overview

Table 74. Eli Lilly Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 75. Eli Lilly Medicine for Osteoarthritis Pain Product

Table 76. Eli Lilly Response to COVID-19 and Related Developments

Table 77. Novartis Business Overview

Table 78. Novartis Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. Novartis Medicine for Osteoarthritis Pain Product

Table 80. Novartis Response to COVID-19 and Related Developments

Table 81. Sanofi Business Overview

Table 82. Sanofi Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Sanofi Medicine for Osteoarthritis Pain Product

Table 84. Sanofi Response to COVID-19 and Related Developments

Table 85. Horizon Pharma Business Overview

Table 86. Horizon Pharma Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. Horizon Pharma Medicine for Osteoarthritis Pain Product

Table 88. Horizon Pharma Response to COVID-19 and Related Developments

Table 89. Abbott Business Overview

Table 90. Abbott Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Abbott Medicine for Osteoarthritis Pain Product

Table 92. Abbott Response to COVID-19 and Related Developments

Table 93. Mylan Business Overview

Table 94. Mylan Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 95. Mylan Medicine for Osteoarthritis Pain Product

Table 96. Mylan Response to COVID-19 and Related Developments

Table 97. Daiichi Sankyo Business Overview

Table 98. Daiichi Sankyo Medicine for Osteoarthritis Pain Production (K Units),

Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 99. Daiichi Sankyo Medicine for Osteoarthritis Pain Product

Table 100. Daiichi Sankyo Response to COVID-19 and Related Developments

Table 101. TEVA Business Overview

Table 102. TEVA Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 103. TEVA Medicine for Osteoarthritis Pain Product

Table 104. TEVA Response to COVID-19 and Related Developments

Table 105. Almatica Pharma Business Overview

Table 106. Almatica Pharma Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 107. Almatica Pharma Medicine for Osteoarthritis Pain Product

Table 108. Almatica Pharma Response to COVID-19 and Related Developments

Table 109. Astellas Pharma Business Overview

Table 110. Astellas Pharma Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 111. Astellas Pharma Medicine for Osteoarthritis Pain Product

Table 112. Astellas Pharma Response to COVID-19 and Related Developments

Table 113. Tide Pharmaceutical Business Overview

Table 114. Tide Pharmaceutical Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 115. Tide Pharmaceutical Medicine for Osteoarthritis Pain Product

Table 116. Tide Pharmaceutical Response to COVID-19 and Related Developments

Table 117. Iroko Pharmaceuticals Business Overview

Table 118. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 119. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product

Table 120. Iroko Pharmaceuticals Response to COVID-19 and Related Developments

Table 121. Hengrui Pharmaceutical Business Overview

Table 122. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 123. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product

Table 124. Hengrui Pharmaceutical Response to COVID-19 and Related Developments

Table 125. Abiogen Pharma Business Overview

Table 126. Abiogen Pharma Medicine for Osteoarthritis Pain Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 127. Abiogen Pharma Medicine for Osteoarthritis Pain Product

Table 128. Abiogen Pharma Response to COVID-19 and Related Developments

Table 129. Medicine for Osteoarthritis Pain Distributors List

Table 130. Medicine for Osteoarthritis Pain Customers List

Table 131. Covid-19 Impact on Medicine for Osteoarthritis Pain Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Medicine for Osteoarthritis Pain Product Picture
- Figure 2. Medicine for Osteoarthritis Pain Market Segmentation
- Figure 3. Research Objectives
- Figure 4. Research Process
- Figure 5. Data Triangulation
- Figure 6. Research Approach
- Figure 7. Commodity Prices-Metals Price Indices
- Figure 8. Commodity Prices- Precious Metal Price Indices
- Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
- Figure 10. Commodity Prices- Food and Beverage Price Indices
- Figure 11. Commodity Prices- Fertilizer Price Indices
- Figure 12. Commodity Prices- Energy Price Indices
- Figure 13. G20+: Economic Policy Responses to COVID-19
- Figure 14. Global Medicine for Osteoarthritis Pain Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US\$ Million)
- Figure 15. Global Medicine for Osteoarthritis Pain Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
- Figure 16. Global Medicine for Osteoarthritis Pain Market Size, Quarterly Growth, 2020-2021 (%)
- Figure 17. Global Medicine for Osteoarthritis Pain Market Size, Market Share by Type, 2019 VS 2020 (%)
- Figure 18. Global Medicine for Osteoarthritis Pain Market Size, Market Share by Application, 2019 VS 2020 (%)
- Figure 19. Global Medicine for Osteoarthritis Pain Market Size Market Share by Region, 2019 VS 2020 (%)
- Figure 20. United States Composite PMI and GDP
- Figure 21. Eurozone Composite PMI and GDP
- Figure 22. Eurozone Core v. Periphery PMI Output Indices
- Figure 23. Core v. Periphery PMI Employment Indices
- Figure 24. UK Composite PMI and GDP
- Figure 25. Caixin China Composite Output Index
- Figure 26. Caixin China General Services Business Activity Index
- Figure 27. Japan Composite Output Index
- Figure 28. South Korea Manufacturing PMI
- Figure 29. India Composite Output Index

Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific Medicine for Osteoarthritis Pain Market Size Market Share, 2019-2021

I would like to order

Product name: COVID-19 Impact on Medicine for Osteoarthritis Pain Market, Global Research Reports 2020-2021

Product link: <https://marketpublishers.com/r/C1C3746CF69EEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1C3746CF69EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

